Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Therapeutic Potential of Adult Progenitor Cells in the Management of Chronic Myocardial Ischemia

Therapeutic Potential of Adult Progenitor Cells in the Management of Chronic Myocardial Ischemia Refractory angina as a result of chronic myocardial ischemia is a common and disabling condition. Adult progenitor cells have emerged as a potential revolutionary treatment for cardiovascular disease. Locally administered adult progenitor cells with particular vasculogenic potential may offer treatment hope for those with chronic ischemia; however, the optimal cell type, dose, delivery mode, and target patient population has not been defined. Preclinical cell therapy studies have shown safety and efficacy sufficient to warrant human trials. Early, small-scale human trials exploring various cell types and delivery modes have shown that most approaches are safe, with modest early efficacy. This overview discusses the rationale and early results for ongoing larger cardiovascular disease trials, with a special emphasis on refractory angina and chronic myocardial ischemia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Therapeutic Potential of Adult Progenitor Cells in the Management of Chronic Myocardial Ischemia

American Journal of Cardiovascular Drugs , Volume 8 (5) – Aug 17, 2012

Loading next page...
 
/lp/springer-journals/therapeutic-potential-of-adult-progenitor-cells-in-the-management-of-2a0iON0iJg

References (95)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200808050-00004
pmid
18828643
Publisher site
See Article on Publisher Site

Abstract

Refractory angina as a result of chronic myocardial ischemia is a common and disabling condition. Adult progenitor cells have emerged as a potential revolutionary treatment for cardiovascular disease. Locally administered adult progenitor cells with particular vasculogenic potential may offer treatment hope for those with chronic ischemia; however, the optimal cell type, dose, delivery mode, and target patient population has not been defined. Preclinical cell therapy studies have shown safety and efficacy sufficient to warrant human trials. Early, small-scale human trials exploring various cell types and delivery modes have shown that most approaches are safe, with modest early efficacy. This overview discusses the rationale and early results for ongoing larger cardiovascular disease trials, with a special emphasis on refractory angina and chronic myocardial ischemia.

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 17, 2012

There are no references for this article.